Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy
about
Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patientsLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensLow Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort StudyEvolution of the uniquely adaptable lentiviral envelope in a natural reservoir host.Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.Association of HIV/AIDS Clinician Warm Line Utilization with Diagnosis and Management of Antiretroviral Treatment Failure in Mozambique: A Retrospective Analysis of Program DataNature, position, and frequency of mutations made in a single cycle of HIV-1 replication.Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcomeGenetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivityThe long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapyDrug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South AfricaEvolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failurePractices to improve identification of adult antiretroviral therapy failure at the Lighthouse Trust clinic in Lilongwe, Malawi.Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, IndiaPrediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian childrenUltrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West AfricaAnthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settingsExtensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines.Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria.Defining treatment failure in resource-rich settings.An ontology-driven method for hierarchical mining of temporal patterns: application to HIV drug resistance research.Rate-limiting Pyrophosphate Release by HIV Reverse Transcriptase Improves Fidelity.Antiretroviral therapy status among people who died of AIDS-related causes from 2009 to 2013 in Brazil: a population-based study.Solid-state nanopore detection of protein complexes: applications in healthcare and protein kinetics.Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe.Accurate prediction of enzyme mutant activity based on a multibody statistical potential.Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression
P2860
Q28483630-A5DD852E-0AA1-494E-921B-F449D4E4302CQ28485321-2744BFCB-CEC4-4434-B04C-DCBCA90C9F44Q28550552-2465560C-D082-412F-9327-4420568D9EAEQ31034710-0A4788CB-A491-45F6-BB74-3C946DC9C3A9Q33636669-E0D6CA83-1136-4D42-A821-DFEBE8CB200FQ33904819-CA8056FB-EC0E-4D3F-8FD8-A2CBB1602058Q34120857-6A139601-5A69-44B0-B770-9262642D2C8BQ34292437-FEE74B3F-F15B-4D9A-A9F9-CFBA8FA9B3E4Q34485122-D7ECD333-4F6D-4E3D-B633-2AABC09043E7Q34717635-1FB3DEE9-BC62-4A29-921B-915FDDA75B15Q34777454-7EB5CB4E-560F-4E43-BBF2-43FDF0E39D1FQ35158051-6933EF01-1196-4657-AAC0-7A172B54BE6DQ35217629-C0A8E46C-0A0B-4079-8BA4-5D97FC650454Q35698801-6DD1F157-ED80-4731-B1C4-B818DB5AF588Q35803429-AA059D2D-C8A9-4DB0-A8F5-30B783BEFBF8Q35917573-648307D2-683C-4276-B42B-9208DBF5FD99Q36379413-84E90B7A-5258-4DDA-A154-1F7607EB2D1AQ36397557-ED73BA41-828E-40D5-B24E-E38F3CC4CE54Q36558909-A9A3BB1A-173A-462A-92EB-8AA225AF4C72Q36793768-A617BD0E-06D0-4DF8-BFD5-6790BA22C5A0Q36793821-2DE12EB2-4A24-4A63-A7BE-E0BC171B0B3AQ36877987-8F7E3440-FE53-42F6-8273-E7901550D40DQ36937877-B0204E13-619E-4D2D-9CB0-6F1B807FAD80Q37147686-45A8F145-CA5F-422A-AE79-1F2519927A6AQ37667776-1E2037A7-8519-494F-A77B-6C3A6DBEF761Q38512880-2A3ECC9F-A170-4F50-83C5-9379FB191966Q39253052-D2CD755B-E2B2-48C6-87EA-D10C99A1C80FQ39328273-EB98DAE2-5D3D-4A57-B64E-08D474923B9FQ39535086-929AE811-A97E-4FB7-98D6-3400C83AEC8FQ42995760-A8A5BF85-11D3-4A1F-9B3B-D1A94E133BC4Q45965059-B9EAEB54-95B0-441C-BB19-1F2C086751D6Q46127990-3B8CE98A-C02A-43BC-A9D2-4E7DEE420996Q46599509-3BA0FAE4-21C3-41D9-8164-E480B31A8B4AQ46692659-D2880EDA-3D42-4502-BC7C-92B6F5062579Q57876975-D1E026DD-5DC3-41E7-A22A-EBF7126DBB7DQ57877709-D453C19C-73AE-44BC-8FFC-03EE74763472
P2860
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evolution of resistance to dru ...... failing antiretroviral therapy
@en
type
label
Evolution of resistance to dru ...... failing antiretroviral therapy
@en
prefLabel
Evolution of resistance to dru ...... failing antiretroviral therapy
@en
P2093
P2860
P1433
P1476
Evolution of resistance to dru ...... failing antiretroviral therapy
@en
P2093
David Katzenstein
David Shilane
Dong-Phuong Nguyen
Jonathan Taylor
Leo Hurley
Rami Kantor
Robert W Shafer
Stephen Follansbee
W Jeffrey Fessel
P2860
P304
P356
10.1097/01.AIDS.0000131358.29586.6B
P407
P577
2004-07-01T00:00:00Z